
Volitionrx Limited (VNRX) Stock Forecast & Price Target
Volitionrx Limited (VNRX) Analyst Ratings
Bulls say
VolitionRX has made significant strides in commercialization, recording its first revenue from the CE-Marked Nu.Q NETs automated assay and expanding evaluations to over 20 hospitals across multiple countries and clinical indications. The company's strategic partnerships, specifically licensing agreements with established leaders like Werfen and Hologic, further elevate its credibility and market potential, signaling a robust human diagnostics licensing strategy. Additionally, VolitionRX's innovative and low-cost blood-based testing solutions, alongside advances in its Nucleosomics platform, position it favorably in a growing market focused on early disease detection and improved patient outcomes.
Bears say
VolitionRX Ltd faces increased dilution risk, leading to a reduction in their price target from $5.0 to $3.0, indicating potential challenges in achieving desired financial performance. This heightened risk may stem from the company’s ongoing need for capital to fund its research and development efforts, which could dilute existing shareholder value. Furthermore, the uncertainty surrounding the commercialization of its Nucleosomics platform and the broader market acceptance of its diagnostic tests contributes to a pessimistic financial outlook.
This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.
Volitionrx Limited (VNRX) Analyst Forecast & Price Prediction
Start investing in Volitionrx Limited (VNRX)
Order type
Buy in
Order amount
Est. shares
0 shares